It shows that GSK is now doing everything to increase production and even looking at alternative ways to improve the relenza product wow....
We can also read from this info that Biota will make a figure around the A$100 Million per year from royalties.
That certainly justifies todays share price and probably a higher value attached to it.
The market likes to know what to expect from Relenza sales and this summs it up very nicely.
I remain upbeat with Biota and believe that the shareprice still does not reflect the company value, keeping in mind the current Cash in bank of around A$70 Million and the current income stream around the A$100 Million per year.
jojo
BTA Price at posting:
$1.38 Sentiment: LT Buy Disclosure: Held
